Browsing by Author "Rueda, Bo"
Now showing items 1-11 of 11
-
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Ince, Tan A.; Sousa, Aurea D.; Jones, Michelle A.; Harrell, J. Chuck; Agoston, Elin S.; Krohn, Marit; Selfors, Laura M.; Liu, Wenbin; Chen, Ken; Yong, Mao; Buchwald, Peter; Wang, Bin; Hale, Katherine S.; Cohick, Evan; Sergent, Petra; Witt, Abigail; Kozhekbaeva, Zhanna; Gao, Sizhen; Agoston, Agoston T.; Merritt, Melissa A.; Foster, Rosemary; Rueda, Bo R.; Crum, Christopher P.; Brugge, Joan S.; Mills, Gordon B. (Nature Pub. Group, 2015)Currently available human tumour cell line panels consist of a small number of lines in each lineage that generally fail to retain the phenotype of the original patient tumour. Here we develop a cell culture medium that ... -
Correlates of the preoperative level of CA125 at presentation of ovarian cancer
Cramer, Daniel William; Vitonis, Allison F.; Welch, William Robert; Terry, Kathryn Lynne; Goodman, Annekathryn; Rueda, Bo Ruben; Berkowitz, Ross Stuart (Elsevier BV, 2010)Objective CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels. We examined the effect of ... -
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer
Garrett, Leslie A.; Growdon, Whitfield B.; Rueda, Bo R.; Foster, Rosemary (BioMed Central, 2016)Background: Pre-clinical studies have demonstrated that natural and synthetic histone deacetylase (HDAC) inhibitors can impede the in vitro and in vivo growth of cell lines from a variety of gynecologic and other malignancies. ... -
Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
Pant, Alok; Lee, Irene I.; Lu, Zhenxiao; Rueda, Bo Ruben; Schink, Julian; Kim, J. Julie (Public Library of Science, 2012)Progestin resistance is a major obstacle to treating early stage, well-differentiated endometrial cancer as well as recurrent endometrial cancer. The mechanism behind the suboptimal response to progestin is not well ... -
Inhibition of Notch Signaling in Combination with Paclitaxel Reduces Platinum-Resistant Ovarian Tumor Growth
Groeneweg, Jolijn W.; DiGloria, Celeste M.; Yuan, Jing; Richardson, William S.; Growdon, Whitfield B.; Sathyanarayanan, Sriram; Foster, Rosemary; Rueda, Bo R. (Frontiers Media S.A., 2014)Introduction: Ovarian cancer (OvCa) is the most lethal gynecologic malignancy in the United States because of chemoresistant recurrent disease. Our objective was to investigate the efficacy of inhibiting the Notch pathway ... -
Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer
Konstantinopoulos, Panagiotis; Cannistra, Stephen Anthony; Fountzilas, Helen; Culhane, Aedin; Pillay, Kamana; Rueda, Bo Ruben; Cramer, Daniel William; Seiden, Michael; Birrer, Michael James; Coukos, George; Zhang, Lin; Quackenbush, John; Spentzos, Dimitrios (Public Library of Science (PLoS), 2011)Background Public data integration may help overcome challenges in clinical implementation of microarray profiles. We integrated several ovarian cancer datasets to identify a reproducible predictor of survival. Met ... -
Leptin-Signaling Inhibition Results in Efficient Anti-Tumor Activity in Estrogen Receptor Positive or Negative Breast Cancer
Rene Gonzalez, Ruben; Watters, Amber; Xu, Yanbo; Singh, Udai P; Mann, David R; Rueda, Bo Ruben; Penichet, Manuel L (BioMed Central, 2009)Introduction: We have shown previously that treatment with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) reduced the expression of vascular endothelial growth factor (VEGF), vascular endothelial growth factor ... -
Metformin Therapy in a Hyperandrogenic Anovulatory Mutant Murine Model with Polycystic Ovarian Syndrome Characteristics Improves Oocyte Maturity during Superovulation
Sabatini, Mary Elizabeth; Guo, Lankai; Lynch, Maureen Patricia; Doyle, Joseph O'Brien; Lee, HoJoon; Rueda, Bo Ruben; Styer, Aaron Kyle (BioMed Central, 2011)Background: Metformin, an oral biguanide traditionally used for the treatment of type 2 diabetes, is widely used for the management of polycystic ovary syndrome (PCOS)-related anovulation. Because of the significant ... -
MicroRNA-15b regulates reversion-inducing cysteine-rich protein with Kazal motifs (RECK) expression in human uterine leiomyoma
Guan, Yichun; Guo, Lankai; Zukerberg, Lawrence; Rueda, Bo R.; Styer, Aaron K. (BioMed Central, 2016)Background: Human uterine leiomyoma (fibroids; LYO) are the most common benign neoplasms in reproductive-aged women. Dysregulated extracellular matrix and irregular LYO reversion-inducing cysteine-rich protein with Kazal ... -
Notch signaling in serous ovarian cancer
Groeneweg, Jolijn W; Foster, Rosemary; Growdon, Whitfield B; Verheijen, René HM; Rueda, Bo R (BioMed Central, 2014)Ovarian cancer is the most lethal of all gynecologic malignancies because women commonly present with advanced stage disease and develop chemotherapy refractory tumors. While cytoreductive surgery followed by platinum based ... -
Prostaglandin F2alpha- and FAS-activating antibody-induced regression of the corpus luteum involves caspase-8 and is defective in caspase-3 deficient mice
Carambula, Silvia F; Pru, James K; Lynch, Maureen Patricia; Matikainen, Tiina; Gonçalves, Paulo Bayard D; Flavell, Richard A; Tilly, Jonathan Lee; Rueda, Bo Ruben (BioMed Central, 2003)We recently demonstrated that caspase-3 is important for apoptosis during spontaneous involution of the corpus luteum (CL). These studies tested if prostaglandin F[sub]2α (PGF[sub]2α) or FAS regulated luteal regression, ...